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ABSTRACT
Background Myopia is a condition of enormous public
health concern, affecting up to 2.5 billion people
worldwide. The most effective treatment to prevent
myopia progression is atropine but at the cost of
accommodative paresis and mydriasis, necessitating the
use of bifocal glasses. Low-dose atropine (0.01%) has
been found to be almost as effective with significantly
reduced side effects. Since there are well-recognised
differences in the effect of atropine between heavily
pigmented Asian eyes and Caucasian eyes, this study
aimed to determine the acceptability and tolerability of
0.01% atropine (by measuring visual performance and
quality of life) as a treatment for myopia control in a
Caucasian population exhibiting light irides.
Methods 14 university students aged 18–27 were
recruited to the study. Participants received one drop of
0.01% atropine daily into each eye over 5 days. A range
of physiological, functional and quality of life measures
were assessed at baseline, day 3 and day 5.
Results The effect of atropine was statistically
significant for pupil size (p=0.04) and responsiveness
(p<0.01). While amplitude of accommodation reduced,
the change was not statistically significant. Visual acuity
(distance and near) and reading speed were not
adversely affected. While there was a slight increase in
symptoms such as glare, overall there was no quality of
life impact associated with the use of low-dose atropine.
Conclusions Overall, 0.01% of atropine was generally
well tolerated bilaterally and no serious adverse effects
were observed. Therefore this dose appears to provide a
viable therapeutic option for myopia control among
Caucasian eyes.
INTRODUCTION
Myopia has now reached pandemic proportions
and is expected to affect a staggering 2.5 billion
people by 2020.1 Yet standard clinical care today
treats only the optical and medical consequences of
this condition, rather than addressing its underlying
biological basis. In developed countries in East and
Southeast Asia, the prevalence of myopia has
doubled in the past 30 years to over 90% of young
adults in some countries.2 Similar extraordinary
increases in prevalence are affecting Western
society, with myopia prevalence doubling to almost
50% among school-leavers in the USA3 and over
50% in parts of Europe,4 including the UK.5 The
existing and future public health implications of
myopic progression and of increasing myopia
prevalence are considerable.
The primary risks associated with myopia pro-
gression relate to its associations with ophthalmic
disease and blindness. Epidemiological studies indi-
cate that myopia is second only to age as a risk
factor for many of the major eye diseases, including
glaucoma, cataract and retinal detachment,6 and is
the primary risk factor in myopic maculopathy.7
Even outside Asia, myopic maculopathy is one of
the leading causes of blindness among working-age
people, including in the UK,8 Ireland,9 Israel10 and
across other parts of Europe.11–13 Atrophic myopic
maculopathy is unique, however, in having no
forms of available treatment, no current treatment
trials and a proven aetiological basis.
The incidence of retinal detachment has been
observed to increase over 45% in Scotland over a
20-year period, a phenomenon that, although
unproven, may well be linked to the evolving
profile of myopia.14 In terms of overall risk, mild
levels of myopia appear to be as dangerous to
ocular health as smoking and hypertension are to
cardiovascular health.6 Although myopia is not cur-
rently considered by clinicians to be a modifiable
risk factor for blindness, the evidence is compelling
that the introduction of a safe and effective method
of reducing myopic progression would have a sig-
nificant public health benefit.
A recent Cochrane review of the interventions
for myopia control reported that there is no con-
clusive evidence that optical control modalities
such as undercorrection, multifocal spectacles or
contact lenses yield benefits in terms of reductions
in the rate of progression, and may, in some
instances, exacerbate the rate of myopia progres-
sion.15 Recent evidence suggests, however, that
contact lenses which correct for peripheral hyper-
opia may have a clinically significant benefit for
myopia control.16 17 The Cochrane review con-
cluded that topical antimuscarinic medication is the
most likely effective treatment to slow myopia
progression.15
Atropine was originally used for myopia control
at its standard 1% dose, and while this proved
highly effective in reducing the rate of axial elong-
ation and myopia progression, it was, unsurpris-
ingly, associated with the expected side effects,
including pupillary dilatation, photophobia, cyclo-
plegia and allergy.18 The most recent evidence
(ATOM2 study), however, in relation to the relative
efficacy of various concentrations of atropine, sug-
gests that, over a 5-year follow-up period, a
low-dose 0.01% concentration actually exhibits the
highest efficacy in slowing myopia progression with
less visual side effects compared with higher doses
of atropine.19 Such a low dose may, therefore,
prove more tolerable and acceptable to patients as a
means of effective myopia control. The ATOM2
study of low-dose atropine was conducted in
Singapore on a population with heavily pigmented
irides. Since race and iris colour are known factors
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that influence cycloplegia, one valid concern about applying
such treatment in lightly pigmented Caucasian eyes is that the
side effect profile may be more severe.20
This study has been designed, therefore, to assess the feasibil-
ity of low-dose atropine (0.01%) for use as a potential myopia
control agent in a Caucasian population exhibiting lightly pig-
mented irides. Specifically, the effect of low-dose atropine on
(1) functional vision measures including visual acuity (VA) and
reading speed; (2) physiological measures including amplitude
of accommodation (AA), pupil size and convergence; and (3)
vision-related quality of life were the primary objectives of the
study.
MATERIALS AND METHODS
University students were invited to participate in this study,
which was approved by the Research Ethics Committee at
Dublin Institute of Technology. Written informed consent was
obtained from all subjects, and the study adhered to the tenets
of the Declaration of Helsinki. Inclusion criteria were age 18+
years, VA better than logMAR 0.3, light irides, refractive error
ranging from emmetropia to 6 D of myopia, Caucasian race, AA
>6 D and normal systemic and ocular health. Volunteers were
to be excluded on the basis of any evidence of a narrow anterior
chamber drainage angle, known allergy to atropine or any sys-
temic condition contraindicating the use of atropine.
Demographic information, including age and gender, were
recorded for each participant. Iris colour was assessed under
ambient room illumination, and eligibility confirmed under slit
lamp biomicroscope illumination (absence of any conspicuous
brown iris melanin pigmentation).
Non-cycloplegic autorefraction (and focimetry of existing
spectacle prescription where relevant) was performed to provide
an estimate of refractive error (Topcon TRK-2P Auto
Kerato-Refractor). Distance VA was measured using the early
treatment of diabetic retinopathy study (ETDRS) logMAR chart
at 6 m. Test letters were randomised on each visit. Near VA was
measured with a reduced logMAR reading chart held at 40 cm.
AA was measured monocularly and binocularly and the near
point of convergence (NPC) was measured binocularly with a
Royal Air Force rule as the average of three measurements.
Reading speed was assessed using the Wilkins Rate of Reading
Test, which was recorded as the number of correctly identified
words per second (WPS). Four separate passages of text were
used to avoid any bias due to familiarity with the text. All of the
above measurements were taken with distance spectacle correc-
tion worn where appropriate.
Pupil size was measured using the Neuroptics VIP-200
Pupillometer. The direct pupillary response was checked using
an light emitting diode (LED) pen torch, and recorded on a
scale ranging from 0 (non-responsive) to 3 (brisk).
Atropine 0.01% was prepared by dilution of unpreserved
atropine 1% minims (Bausch & Lomb) into a well-tolerated
ocular vehicle (Tears Naturale, Alcon Laboratories).
On completion of all baseline tests, one drop of 0.01% atro-
pine was instilled in both eyes of eligible participants.
Participants returned to the clinic at the same time each day for
repeat instillation of the eyedrops on four subsequent days. Each
of the baseline tests were repeated on two subsequent days,
yielding a total of three sets of measurements for each partici-
pant (baseline (day 1), day 3, final (day 5)).
Participants also completed the visual function-14 quality of
life questionnaire at baseline and on the final visit to explore the
presence of any difficulties affecting routine vision-related activ-
ities. Subjects were required to assign their level of difficulty
with each of the 14 vision-related tasks into one of the follow-
ing grades: none, a little, moderate, great deal and unable to do.
At the final visit, participants were also asked the generic ques-
tion, ‘Was the use of atropine eyedrops (a) acceptable/tolerable
to you as a therapy for myopia control (yes or no?) and (b)
compatible with the continuation of normal vision-related activ-
ities such as reading and studying (yes or no?)’.
Statistical analysis
All statistical analysis was performed using the statistical soft-
ware package SPSS (V.22.0; IBM, New York, New York, USA).
The Shapiro–Wilk’s test was used to determine normality of the
data distributions. A one-way repeated measures analysis of vari-
ance (RM-ANOVA), including Greenhouse–Geisser correction
for violations of sphericity and post-hoc tests where appropriate,
was used to explore the effect of the atropine preparation on
measures of visual function across the duration of the study. A
statistical significance level of 5% was adopted throughout the
analysis.
RESULTS
A total of 14 participants were enrolled in the study, with equal
gender representation and comprising 11 myopes (refractive
error range −0.75 to −3.25 D spherical equivalent) and three
emmetropes. The mean (SD) age of participants was 22 (3).
Ocular physiology
On average, photopic pupil size increased by 1.31 mm (OD,
right eye) and 1.08 mm (OS, left eye). The degree of change in
pupil size was largest initially, with a 13.1%–18.9% increase
between the baseline and day 3 measures, which then moder-
ated to a 4.1%–4.9% further increase between day 3 and day
5. RM-ANOVA revealed that the change in pupil size was statis-
tically significant in each eye (p=0.04). Post-hoc analysis using a
paired t test revealed that the pupil size at the final visit was stat-
istically significantly different from baseline (p=0.04), but not
from the day 3 measure (p=0.79). Pupillary response also
became statistically significantly more sluggish by the final visit
(p<0.01). The NPC receded slightly at the final visit relative to
baseline, but the difference was not statistically significant
(p=0.25). Binocular AA exhibited an 11% reduction over the
study duration (figure 1), but the change was not statistically sig-
nificant (p=0.08).
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Figure 1 Change in amplitude of accommodation during the course
of the study.
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Visual function
Reading speed remained essentially unchanged throughout the
study (figure 2), ranging from 3.29 WPS at baseline to 3.25
WPS at completion (p=0.45). Furthermore, distance VA exhib-
ited only a one-letter change that was not statistically significant,
while near VA remained unchanged throughout.
The mean (SD) of all clinical measurements at baseline, and
across all three subsequent study visits, along with the
RM-ANOVA are presented in table 1.
Quality of life
At baseline, all 14 participants reported no difficulty with any
of the 14 vision-related activities contained in the visual
function-14 questionnaire. At the final visit four subjects
remained entirely asymptomatic. Eight subjects reported a one-
grade increase in their level of difficulty (from ‘none’ to ‘a
little’) with one of the 14 vision-related tasks, while two subjects
reported an identical one-grade increase in their level of diffi-
culty in two of the 14 vision-related tasks. Glare was the most
commonly reported symptom by six subjects.
In response to the additional quality of life questions, all 14
reported that (1) atropine was acceptable/tolerable to them as a
form of therapy for myopia control and (2) atropine was com-
patible with the continuation of normal vision-related activities.
DISCUSSION
As well as being effective, any intervention that requires treat-
ment over an extended period of time must also be well toler-
ated. The results of this study show that low-dose atropine has
minimal impact on accommodation, reading speed and visually
dependent daily activities. The age profile of this study was
higher than in the ATOM2 study (age group: 6–12 years), but
the age-related reduction in AA means that older subjects are
more sensitive to the cycloplegic side effects of low-dose atro-
pine. The inclusion of university students, at a time of year
when course exams were ongoing, meant that the visual
demands of study participants were particularly exacting, more
so than would be typical of younger children. In addition, the
higher rate of adult-onset myopia in Europe relative to Asia
requires that treatments (if available) be applied to older subjects
than were recruited to the ATOM2 study.
Atropine is a competitive and non-selective antagonist of the
muscarinic acetylcholine receptors. In ophthalmic use, topical
atropine is used as a cycloplegic, to temporarily paralyse the
accommodation reflex, and as a mydriatic, to dilate the pupils.
Atropine at standard doses reaches peak cycloplegia within 1 h
and degrades slowly, wearing off in 7–14 days, and so it is gen-
erally used as a therapeutic agent rather than as a diagnostic
drug, for example, in the treatment of anterior uveitis or ambly-
opia in children. Despite established merits for myopia control,
the adverse effects associated with the standard 1% dose of atro-
pine (eg, blurred near vision which is exploited as a monocular
penalisation technique in amblyopia treatment) have inhibited
its emergence as a viable control therapy.15
A serendipitous discovery in a trial conducted in Singapore
has provided a solution to the side effects observed at the 1%
dose, by demonstrating that low-dose atropine (0.01%) remains
effective at reducing myopic progression, while having minimal
impact on pupil size and range of accommodation.19 21 22 The
efficacy of the 0.5% and 0.1% dose was effectively equal to the
1% standard dose. Myopia progression after 2 years in the
1.0%, 0.5% and 0.1% groups was minimal at −0.29 D,
−0.30 D and −0.38 D, respectively, while the progression in the
0.01% group was not statistically significantly different at
0.49 D. That 0.01% remains effective relates to the very high
level of affinity atropine has to muscarinic receptors. At normal
clinical doses atropine blocks all receptor subtypes (M1–M5),
but the 0.01% dose has minimal impact on pupil size and
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Figure 2 Change in reading speed during the course of the study.
Table 1 Impact of low-dose (0.01%) atropine on measures of ocular physiology and visual function
Variable Baseline (day 1) Day 3 Final (day 5)
RM-ANOVA
p Value
Distance VA OD −0.10 (0.10) −0.08 (0.07) −0.08 (0.05) 0.547
Distance VA OS −0.10 (0.07) −0.08 (0.06) −0.08 (0.05) 0.644
Near VA OD N5 N5 N5 –
Near VA OS N5 N5 N5 –
AA OD 9.5 D (1.78) 9.3 D (1.44) 9.1 D (2.83) 0.18
AA OS 9.3 D (2.14) 9.8 D (1.94) 8.6 D (1.90) 0.11
AA OU 10.2 D (1.42) 10 D (1.39) 9.1 D (2.12) 0.08
Pupil size (mm) OD 5.51 (1.74) 6.55 (1.12) 6.82 (0.61) 0.04
Pupil size (mm) OS 5.81 (1.73) 6.57 (1.32) 6.89 (0.92) 0.04
Reading speed (WPS) 3.36 (0.55) 3.16 (0.54) 3.25 (0.45) 0.12
Pupillary responses 3.0 (0.00) 2.8 (0.45) 1.1 (0.90) 0.00
NPC (cm) 6.8 (2.43) 7.0 (2.19) 8. (3.24) 0.25
Statistically significant findings are highlighted in bold text.
AA, amplitude of accommodation; NPC, near point of convergence; OD, right eye; OS, left eye; OU, both eyes; RM-ANOVA, repeated measures analysis of variance; VA, visual acuity;
WPS, words per second.
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accommodation (M3 receptors),23 while retaining most of its
beneficial effects on myopic progression (M1 and M4).24 An
additional advantage of the low-dose atropine is that a rebound
acceleration of myopia progression observed on cessation of 1%
atropine treatment is not observed at this 0.01% concentra-
tion.22 The benefit is such that after 5 years of follow-up, the
progression of myopia is actually least in the 0.01% group rela-
tive to all higher concentrations.19 A recent retrospective case–
control study has also reported that atropine 0.01% eyedrops
significantly reduced the rate of myopic progression over 1 year
with minimal side effects (progression −0.1 D compared with
−0.6 D for controls). This study suggests that the low dose
appears most effective in children with low initial myopia but
may not control rapid myopic progression in some patients.25
Topical antimuscarinic drugs are unusual in that there is a
well-described racial variation in sensitivity to such drugs that
relates to the amount of pigmentation (specifically melanin)
within the iris.20 26 Iris melanin content is important in the
context of atropine use as melanin is known to sequester anti-
cholinergic compounds.27 An eye with dark brown irides has
two to four times more ocular melanin than one with blue
irides.28 The effect is such that the same concentration of drug
has less cycloplegic and mydriatic effect on darker relative to
lighter irides. Melanin-bound atropine is slowly released such
that recovery from the effect on accommodation and pupil size
is longer seen in darker irides. The ability of melanin to bind
and alter the pharmacokinetics of a drug such as atropine may
have an impact on the tolerability or efficacy of the therapy, and
therefore limits the extrapolation of results from a trial con-
ducted in Asia to Europe. While one might expect increased
efficacy of atropine in Caucasian eyes, there is also the concern
that the possible side effects might be worse. Such racial differ-
ences may, therefore, reduce the acceptability of the therapy in
populations with a higher proportion of Caucasians.
The physiological, functional and quality of life impact of
low-dose atropine in a Caucasian population are critical in
terms of the future acceptability of atropine as a viable thera-
peutic intervention. Importantly, this study included only those
with light irides of most concern from a safety and tolerability
perspective.
As expected, the use of atropine was associated with physio-
logical changes such as pupillary dilatation, decreased pupillary
response and accommodative amplitude. The magnitude of such
changes appears small and was not associated with any detectable
loss of functional vision. Reading speed and VA, both distance
and near, remained essentially unchanged throughout the study.
There was, however, some quality of life impact associated
with the physiological response to the low-dose atropine. Only
four participants remained entirely asymptomatic, and it is
unsurprising to note that glare, presumably associated with the
reduced pupillary responsiveness and increase in pupil size, was
the most frequently cited quality of life impact. The impact
again was minimal, and perhaps the most important finding of
this pilot investigation is that all 14 participants found the use
of low-dose atropine tolerable, and it did not adversely impact
the continuation of their exacting visual activities. These results
are compatible with those obtained among Asian participants
with darker irides. In particular, the 0.01% dose employed in
the ATOM2 trial was not associated with the side effects typical
of the standard clinical dose.19 21 Even the reduced 0.5% and
0.1% doses employed in ATOM2 were associated with a nega-
tive impact on participant quality of life, with 70% and 61% of
participants on these respective doses requesting the prescrip-
tion of progressive addition lenses to assist their reading during
the study, compared with only 6% in the 0.01% group. More
recently, a 0.02% concentration has been established as the
maximum atropine dose that can be administered in Asian eyes
without a clinical impact on vision.29
The results of this study indicate, therefore, that 0.01% of
atropine instilled bilaterally over a period of 5 days was gener-
ally well tolerated without serious adverse effects. While these
findings are limited in terms of sample size and duration, we
would suggest that, as a pilot investigation, they are sufficient to
confirm the acceptability and minimal side effect profile of
low-dose atropine for myopia control in a Caucasian population
likely to exhibit lighter irides than is typical in Asia.
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